These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21295437)

  • 21. Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India.
    Raizada N; Chauhan LS; Babu BS; Thakur R; Khera A; Wares DF; Sahu S; Bachani D; Rewari BB; Dewan PK
    PLoS One; 2009 Jun; 4(6):e5999. PubMed ID: 19543396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members.
    Mermin J; Lule J; Ekwaru JP; Downing R; Hughes P; Bunnell R; Malamba S; Ransom R; Kaharuza F; Coutinho A; Kigozi A; Quick R
    AIDS; 2005 Jul; 19(10):1035-42. PubMed ID: 15958834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda.
    Pitter C; Kahn JG; Marseille E; Lule JR; McFarland DA; Ekwaru JP; Bunnell R; Coutinho A; Mermin J
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):336-43. PubMed ID: 17327758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda.
    Watera C; Todd J; Muwonge R; Whitworth J; Nakiyingi-Miiro J; Brink A; Miiro G; Antvelink L; Kamali A; French N; Mermin J
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):373-8. PubMed ID: 16810124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.
    Saadani Hassani A; Marston BJ; Kaplan JE
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S257-69. PubMed ID: 25768865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Operational research in Malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV.
    Harries AD; Zachariah R; Chimzizi R; Salaniponi F; Gausi F; Kanyerere H; Schouten EJ; Jahn A; Makombe SD; Chimbwandira FM; Mpunga J
    BMC Public Health; 2011 Jul; 11():593. PubMed ID: 21794154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival status and its predictors among undernourished children on antiretroviral therapy in Bahir Dar city, Northwest Ethiopia, 2010 - 2020, a multicenter retrospective cohort study.
    Moga Lencha F; Mekonnen Workie H; Tadesse Mequanint F; Jebero Zaza Z
    BMC Pediatr; 2024 Apr; 24(1):290. PubMed ID: 38689230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis.
    Mbeye NM; ter Kuile FO; Davies MA; Phiri KS; Egger M; Wandeler G;
    Trop Med Int Health; 2014 Sep; 19(9):1057-67. PubMed ID: 25039469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of adverse outcomes in HIV-1-infected children receiving combination antiretroviral treatment: results from a DREAM cohort in sub-Saharan Africa.
    Marazzi MC; De Luca S; Palombi L; Scarcella P; Ciccacci F; Ceffa S; Nielsen-Saines K; De Luca A; Mancinelli S; Gennaro E; Zimba I; Liotta G; Buonomo E
    Pediatr Infect Dis J; 2014 Mar; 33(3):295-300. PubMed ID: 23799517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral Therapy in Severely Malnourished, HIV-infected Children in Asia.
    Boettiger DC; Aurpibul L; Hudaya DM; Fong SM; Lumbiganon P; Saphonn V; Truong KH; Hansudewechakul R; Nguyen LV; Do VC; Bunupuradah T; Chokephaibulkit K; Nik Yusoff NK; Kumarasamy N; Wati DK; Razali KA; Kariminia A;
    Pediatr Infect Dis J; 2016 May; 35(5):e144-51. PubMed ID: 26835972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries.
    Grimwade K; Gilks C
    Curr Opin Infect Dis; 2001 Oct; 14(5):507-12. PubMed ID: 11964869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence rate of tuberculosis and its associated factors among HIV-positive persons in Sub-Saharan Africa: a systematic review and meta-analysis.
    Wondmeneh TG; Mekonnen AT
    BMC Infect Dis; 2023 Sep; 23(1):613. PubMed ID: 37723415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.
    Post FA; Szubert AJ; Prendergast AJ; Johnston V; Lyall H; Fitzgerald F; Musiime V; Musoro G; Chepkorir P; Agutu C; Mallewa J; Rajapakse C; Wilkes H; Hakim J; Mugyenyi P; Walker AS; Gibb DM; Pett SL;
    Clin Infect Dis; 2018 Mar; 66(suppl_2):S132-S139. PubMed ID: 29514234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.
    Hoffmann CJ; Fielding KL; Charalambous S; Innes C; Chaisson RE; Grant AD; Churchyard GJ
    AIDS; 2010 Jul; 24(11):1709-16. PubMed ID: 20495439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brief Report: Cessation of Long-Term Cotrimoxazole Prophylaxis in HIV-Infected Children Does Not Alter the Carriage of Antimicrobial Resistance Genes.
    Francis F; Gough EK; Edens TJ; Berejena C; Bwakura-Dangarembizi M; Shonhai A; Nathoo KJ; Glass M; Gibb DM; Prendergast AJ; Manges AR
    J Acquir Immune Defic Syndr; 2020 Dec; 85(5):601-605. PubMed ID: 32852361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.
    Anywaine Z; Abaasa A; Levin J; Kasirye R; Kamali A; Grosskurth H; Munderi P; Nunn A
    Contemp Clin Trials; 2015 Jul; 43():100-4. PubMed ID: 26009024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
    Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
    Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.
    Ryan M; Griffin S; Chitah B; Walker AS; Mulenga V; Kalolo D; Hawkins N; Merry C; Barry MG; Chintu C; Sculpher MJ; Gibb DM
    AIDS; 2008 Mar; 22(6):749-57. PubMed ID: 18356605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of mortality among children on Antiretroviral Therapy at a referral hospital, Northwest Ethiopia: a retrospective follow up study.
    Koye DN; Ayele TA; Zeleke BM
    BMC Pediatr; 2012 Oct; 12():161. PubMed ID: 23043325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study.
    Mermin J; Were W; Ekwaru JP; Moore D; Downing R; Behumbiize P; Lule JR; Coutinho A; Tappero J; Bunnell R
    Lancet; 2008 Mar; 371(9614):752-9. PubMed ID: 18313504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.